Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome

Therapeutic Advances in Cardiovascular Disease

Volumn 6, Issue 4, 2012, Pages 141-147

  Suzuki, Hiromichi ^a   Shuto, Hiroshi ^b   Shuto, Chizuru ^b   Ohara, Ikkou ^c   Inokuma, Shigehisa ^d   Abe, Yoshiko ^e   Sukigara, Minoru ^f  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Development Minami Koshigaya Kenshinkai Clinic   (Japan)

^c Synthesis Clinic Medical Co   (Japan)

^d Development Inokuma Clinic   (Japan)

^e Development Saitama Hospital Medical Co   (Japan)

^f Development Sukigara Clinic   (Japan)

Author keywords

aldosterone blocker; angiotensin receptor antagonist; calcium channel blocker; metabolic syndrome; renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; EPLERENONE;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; METABOLIC SYNDROME X; MICROALBUMINURIA; MULTICENTER STUDY; NAUSEA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 84865071779     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712452191     Document Type: Article

References (30)

1. Bao Y. Shang X. Zhou L. Hu R. Li Y. Ding W. (2011) Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci 7: 247–256.
2. Briet M. Schiffrin E. (2011) The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 13: 163–172.
3. Burgess E. Lacourciere Y. Ruilope-Urioste L. Oparil S. Kleiman J. Krause S. et al. (2003) Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 25: 2388–2404.
4. Chen J. Muntner P. Hamm L. Jones D. Batuman V. Fonseca V. et al. (2004) The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140: 167–174.
5. Croom K. Perry C. (2005) Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs 5: 51–69.
6. de Gasparo M. Whitebread S. Preiswerk G. Jeunemaitre X. Corvol P. Menard J. (1989) Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 32: 223–227.
7. Flack J. Oparil S. Pratt J. Roniker B. Garthwaite S. Kleiman J. et al. (2003) Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41: 1148–1155.
8. Kidambi S. Kotchen J. Grim C. Raff H. Mao J. Singh R. et al. (2007) Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49: 704–711.
9. Kosaka H. Hirayama K. Yoda N. Sasaki K. Kitayama T. Kusaka H. et al. (2010) The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 635: 49–55.
10. Krum H. Nolly H. Workman D. He W. Roniker B. Krause S. et al. (2002) Efficacy of eplerenone added to renin–angiotensin blockade in hypertensive patients. Hypertension 40: 117–123.
11. Lane D. Shah S. Beevers D. (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25: 891–894.
12. Li W. Chiu F. Chien Y. Lin J. Hwang J. (2011) Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome. Intern Med 50: 1143–1147.
13. Manrique C. Lastra G. Gardner M. Sowers J. (2009) The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 93: 569–582.
14. Matsuzaki M. Ogihara T. Umemoto S. Rakugi H. Matsuoka H. Shimada K. et al. (2011) Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 29: 1649–1659.
15. McMahon E. (2001) Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 1: 190–196.
16. Miller A. Srivastava P. (2001) Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. Cardiol Clin 19: 195–202.
17. Modan M. Halkin H. (1991) Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care 14: 470–487.
18. Nishizaka M. Zaman M. Calhoun D. (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16: 925–930.
19. Ouzan J. Perault C. Lincoff A. Carre E. Mertes M. (2002) The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15: 333–339.
20. Pitt B. (2004) Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217: 53–58.
21. Pitt B. Remme W. Zannad F. Neaton J. Martinez F. Roniker B. et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321.
22. Reyes A. Leary W. Crippa G. Maranhão M. Hernández-Hernández R. (2005) The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med 16: 3–11.
23. Sato A. Fukuda S. (2010) Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 24: 387–394.
24. Schrier R. Masoumi A. Elhassan E. (2010) Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 5: 1132–1140.
25. Sharabi Y. Adler E. Shamis A. Nussinovitch N. Markovitz A. Grossman E. (2006) Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19: 750–755.
26. Sowers J. Whaley-Connell A. Epstein M. (2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150: 776–783.
27. Vaclavik J. Sedlak R. Plachy M. Navratil K. Plasek J. Jarkovsky J. et al. (2011) Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57: 1069–1075.
28. Wang T. Larson M. Keyes M. Levy D. Benjamin E. Vasan R. (2007) Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115: 1345–1353.
29. White W. Duprez D. Hillaire R. Krause S. Roniker B. Kuse-Hamilton J. et al. (2003) Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021–1026.
30. Williams G. Burgess E. Kolloch R. Ruilope L. Niegowska J. Kipnes M. et al. (2004) Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93: 990–996.